Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICU MedicalICUI +0.17%81 EV-to-EBIT is 66.93 as of Aug. 21, 2026, which is 34% above its 10-year median of 50.01. GuruFocus rates ICUI with a GF Score™ of 81/100 and a GF Value™ of $120.63 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 473 Medical Devices & Instruments companies, ICU Medical ranks worse than 90.49% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
ICU Medical's Enterprise Value for the quarter that ended in Jun. 2026 was $4,639 Mil.
ICU Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical EV-to-EBIT Related Terms
ICU Medical EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for ICU Medical's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, ICU Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICU Medical EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where ICU Medical's EV-to-EBIT falls into.
ICU Medical's current Enterprise Value is $5,546 Mil.
ICU Medical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $83 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ICU Medical (ICUI) has a EV-to-EBIT of 66.93 as of Aug. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ICU Medical and its competitors. This is 34% above median its historical median of 50.01. According to the industry distribution chart, ICU Medical ranks #428 out of 473 companies in the Medical Devices & Instruments industry, placing it in the top 90.5%.
Is ICU Medical's EV-to-EBIT too high?
ICU Medical's current EV-to-EBIT of 66.93 is 34% above median its 10-year median of 50.01. The Medical Devices & Instruments industry median EV-to-EBIT is 18.87. ICU Medical's value of 66.93 is 254.7% above this industry median. Based on the distribution chart, ICU Medical ranks #428 out of 473 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ICU Medical has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's EV-to-EBIT compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #428 out of 473 companies for EV-to-EBIT. This places ICU Medical in the lower half of its industry. The industry median EV-to-EBIT is 18.87. ICU Medical's value of 66.93 is 254.7% above this benchmark. While the company's 10-year median is 50.01 vs. the industry median of 18.87, ICU Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.87, based on 473 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICU Medical's current EV-to-EBIT of 66.93 is 254.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on ICU Medical and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICU Medical's current EV-to-EBIT is 66.93, which is 34% above median its own 10-year median of 50.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (ICUI) is currently considered Significantly Overvalued. The stock's GF Value™ is $120.63, compared to a current price of $183.00 — trading 51.7% above its estimated fair value. The current EV-to-EBIT is 66.93, which is 34% above median its 10-year median of 50.01 and 254.7% above the Medical Devices & Instruments industry median of 18.87. ICU Medical's overall GF Score™ is 81/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For ICU Medical (ICUI), the current EV-to-EBIT is 66.93 as of Aug. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICU Medical (ICUI) Overvalued in 2026?
Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued.
The current stock price of $183.00 is trading 51.7% above its estimated GF Value™ of $120.63.
GuruFocus considers ICU Medical to be Significantly Overvalued.
Key valuation signals for ICUI:
EV-to-EBIT: 66.93 (34% above median its 10-year median of 50.01)
GF Value™: $120.63 vs. price of $183.00 (51.7% above fair value)
Industry Position: 254.7% above the Medical Devices & Instruments median (#428 of 473)
No single metric tells the full story. See the ICUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
81GF Score
Get the complete analysis for ICUI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ICUI has been successfully added to your 
